Study of LP-118, Ponatinib, Vincristine, and Dexamethasone for Relapsed/Refractory ALL or LBL
This study is for adults aged 18 and older who have acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or not responded to previous treatments. It is testing a new experimental drug called LP-118 along with ponatinib (an FDA-approved drug for a type of leukemia), vincristine, and dexamethasone. The main goal is to find the safest and most effective dose of LP-118 when given with these other medications. The study plans to enroll about 15 participants. The study is currently unclear about its status.
- Study design
- This is an interventional study planning to enroll 15 participants. It aims to find the best dose of LP-118 in combination with other drugs.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary safety endpoint is measured at 36 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
At a glance
Conditions
NCT06207123
Where you'd take part
This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinoisstudy coordinator listed
Recruiting
University of Rochester Medical Center, Wilmot Cancer Center
Rochester, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Recommended Phase II Dose To demonstrate safety and to identify the recommended phase II dose for combination of LP-118, ponatinib, vincristine and dexamethasone36 weeks
Recommended phase II dose for combination of LP-118, ponatinib, vincristine and dexamethasone as assessed by rate of dose-limiting toxicities among study participants.